Humoral antibody response to bovine leukemia virus infection in cattle and sheep.

In this study, 345 cattle from 7 herds with a history of lymphosarcoma were tested for antibody to BLV antigens by three serological methods, namely immunodiffusion using a bovine leukemia virus glycoprotein with a molecular weight of 60,000 as antigen, and radioimmunoassay using a bovine leukemia virus glycoprotein with a molecular weight of 60,000 and a bovine leukemia virus protein with a molecular weight of 24,000 as antigen. The three tests under comparison agreed for 335 animals, 240 being negative in the three tests, and 95 being positive. Results were variable in ten cases only. Glycoprotein with a molecular weight of 60,000 antibody titers were systematically higher than were protein with a molecular weight of 24,000 antibody titers in bovine sera and milk, as well as in sera of experimentally infected sheep. In the latter case, antibodies to bovine leukemia virus antigens reached maximal values at the animal death in the tumor phase of the disease. Ratios of serum antiglycoprotein titer to milk titer varied between 4 and 117, showing that, if milk pools are to be used in surveys of bovine leukemia virus infection, use of very sensitive techniques of detection is mandatory.

Bovine leukemia virus, a versatile agent with various pathogenic effects in various animal species.

The bovine leukemia virus is the etiological agent of a chronic lymphatic leukemia in cows, sheep, and goats. The same virus seems to induce a kind of wasting disease in experimentally infected rabbits. Antibodies to highly purified bovine leukemia viral Mr 51,000 glycoprotein and Mr 24,000 protein cross-react with human T-lymphotropic virus III/lymphadenopathy-associated virus antigens present in cultured lymphocytes of African patients suffering from acquired immune deficiency syndrome. Bovine leukemia virus has many structural and functional characteristics in common with the human T-lymphotropic viruses. The most striking feature of these retroviruses is the existence of a long open reading frame located at the 3' side of the provirus between the right end of the 3' side of env gene and the left end of the long terminal repeat. It is believed that the long open reading frame protein product acts in trans upon a number of genes to account for the biological effects of the virus.

Experimental transmission of enzootic bovine leukosis to sheep: latency period of the tumoral disease.

In the field of viral oncogenesis the latency period is the interval between detectable establishment of infection and appearance of a tumor. Between 1969 and 1985, a total of 60 sheep died with lymphosarcoma. They were inoculated with BLV-positive blood from various donor cows, by various routes, at various ages, etc. A statistical analysis was performed trying to find a correlation between the length of the latency period and, on the other hand, one or more factors, such as sex, family lineage, identity of the dam, age at inoculation, route of inoculation, or origin of the inoculum. None of the above mentioned parameters has a significant effect on the length of the latency period. In two series of sheep inoculated with decreasing number of lymphocytes from BLV-positive donor cows, hematological disorders and tumors appeared at first in recipient animals inoculated with the higher doses of infectious blood. Thus, the inoculated dose has an effect upon the length of the latency period; the higher the dose inoculated, the shorter the latency period. This finding suggests an explanation to the natural occurrence of multiple case herds as opposed to no-tumor case herds. A multiple case herd fulfills two conditions: the presence of a good donor and an efficient route of transmission allowing the transfer to the recipient of the optimal amount of infected blood.

B cells from bovine leukemia virus- (BLV) infected sheep with hematological disorders express the CD5 T cell marker.

Though peripheral blood B cells from healthy sheep were known to be devoid of the CD5 T cell marker, it appears from our study that most B cells from bovine leukemia virus- (BLV) infected sheep with hematological disorders express both the CD5 marker and surface IgM. The possible meaning of this T cell marker expression on B cells from BLV-infected sheep is briefly discussed.

Bovine leukemia virus (BLV)-infected B-cells express a marker similar to the CD5 T cell marker.

In the course of generating monoclonal antibodies to bovine thymus-dependent differentiation antigens, we were able to characterize an antibody, termed 8C11, that detects an antigen shared by a majority of thymocytes and peripheral T cells (in blood and thymus-dependent area of spleen and lymph-nodes), but undetectable on normal B cells. However, this antibody was reactive with B cells from cows infected with bovine leukemia virus (BLV). These BLV-infected B cells were found to express simultaneously high concentrations of both surface IgM and 8C11-detected antigen. The antigen recognized by this antibody was shown to be a 67.5 kDa molecule. Because similar findings have been made on mouse myelomas and on human chronic leukemia cells, where this antigen was considered to be the equivalent of mouse Ly-1 antigen and human Leu-1 or CD5 antigen, the T cell antigen detected on BLV-infected cells could be the bovine counterpart of the CD5 antigen. By another way, it has been found that the CD5 T cell antigen is also present on a minor subpopulation of B cells in the spleen but not in the blood. We suggest that in the bovine a similar B cell subpopulation should be the BLV target and expand as a consequence of viral insertion, leading to the persistent lymphocytosis observed on BLV-infected animals.

Experimental transmission of enzootic bovine leukosis to cattle, sheep and goats: infectious doses of blood and incubation period of the disease.

A group of 49 BLV-free recipient animals (24 cattle, 15 sheep and 10 goats) were inoculated intradermally with serial dilutions of blood collected on two BLV-positive donor cows. One donor had a high lymphocytosis and high antibody titers to gpBLV antigens; these two parameters were low for the second donor. The number of lymphocytes which induced BLV infection in recipient animals varied widely with the donor. The high infectivity of a donor seemed to be correlated with high lymphocytosis and high antibody titers to gpBLV antigens. Identification and removal of infectious animals would reduce or stop the spread of the infection in a herd, and could be used in the strategy to eradicate the disease. A given inoculum can be infectious in sheep and, at the same time, harmless in cattle. The incubation periods, apparently shorter in sheep, were generally in the range from 2 to 5 weeks for the three species, and exceptionally above.

Epitopes of bovine leukemia virus glycoprotein gp51 recognized by sera of infected cattle and sheep.

Sera of BLV-infected cattle and sheep are tested for their reactivity with different gp51 subregions by competition with radiolabeled monoclonal antibodies directed against 8 different gp51 epitopes. Sheep antisera are found to be very polyvalent, since they are able to displace the fixation of any of the mouse monoclonal antibodies to gp51. Bovine antisera do not display significant competition with monoclonal antibodies direct against 5 out of 8 gp51 epitopes. The bovine antibody response to gp51 is focused to a limited subregion of this molecule, bearing 3 epitopes (F, G and H) recognized by antibodies with virus-neutralizing activity. The differential reactivity of cattle and sheep antisera to BLV gp51 is discussed in relation to the pathology of BLV infection in these two species.

Experimental infection of sheep and goat with bovine leukemia virus: localization of proviral information on the target cells.

Bovine leukemia virus (BLV) proviral integration was studied in the DNA from circulating leucocytes or tumor cells of sheep and goats experimentally infected with BLV. Southern blot analysis of infected cell DNA for BLV proviral sequences indicate that: (1) the provirus may be found as unintegrated molecules in the circulating leucocytes of infected sheep; (2) the provirus is integrated at many sites in the genome of the leucocytes of infected goats and occasionally in infected sheep; (3) the provirus is present at only a few sites in the DNA of sheep or goat tumor cell clones. A second case of goat lymphosarcoma is also reported.

Use of two monoclonal antibodies in an ELISA test for the detection of antibodies to bovine leukaemia virus envelope protein gp51.

A competition ELISA technique involving two monoclonal anti-gp51 antibodies has been developed for the detection of bovine leukaemia virus (BLV) antibodies. Precoated gp51 antigen-microtitre plates were obtained by incubation of plastic adsorbed monoclonal antibody with a non-purified BLV preparation. Samples to be tested were incubated in the wells of the gp51-coated plates; the presence of anti-gp51 antibodies was indicated by competition for antigen binding with an enzyme linked monoclonal antibody directed to an important epitope on gp51. This test is as sensitive as a routinely used indirect ELISA test; it is highly specific, reliable and easy to perform.

Use of monoclonal antibody in an ELISA test for the detection of antibodies to bovine leukaemia virus.

A variant of the ELISA technique, involving a monoclonal anti-gp51 antibody yields a highly sensitive method for the detection of bovine leukaemia virus (BLV) antibodies. The gp51 antigen-coated microtitre plates are obtained by incubation of plastic-adsorbed monoclonal antibodies with a non-purified mixture of BLV antigens. Sera to be tested are incubated in the wells of the gp51-coated plates and bound antibodies are revealed by an enzyme-linked antibovine immunoglobulin reagent. This test is as sensitive as liquid phase radioimmunoassay using the same gp51 antigen and thus appears as a highly sensitive, practical, rapid and cheap method for the detection of BLV antibodies.

Bovine leukaemia: facts and hypotheses derived from the study of an infectious cancer.

Bovine leukaemia virus (BLV) is the etiological agent of chronic lymphatic leukaemia/lymphoma in cows, sheep and goats. Infection without neoplastic transformation was also obtained in pigs, rhesus monkeys, chimpanzees, rabbits and observed in capybaras and water-buffaloes. Structurally and functionally, BLV is a relative of human T lymphotropic viruses 1 and 2 (HTLV-I and HTLV-II) In humans, HTLV-I induces a T-cell leukaemia and its type 2 counterpart has been found in dermatopathic lymphadenopathy, hairy T-cell leukaemia and prolymphocytic leukaemia cases. At variance with HTLV-I, BLV has not been associated with neurological diseases of the degenerative type. Bovine leukaemia virus, HTLV-I and HTLV-II show clearcut sequence homologies. The pathology of the BLV-induced disease, most notably the absence of chronic viraemia, a long latency period and lack of preferred proviral integration sites in tumours, is similar to that of adult T-cell leukaemia/lymphoma induced by HTLV-I. The most striking feature of these three naturally transmitted leukaemia viruses is the X region located between the env gene and the long terminal repeat (LTR) sequence. The X region contains several overlapping long open reading frames. One of them, designated XBL-I, encodes a trans-activator function capable of increasing the level of gene expression directed by BLV-LTR and most probably is involved in "genetic instability" of BLV-infected cells of the B cell lineage. The "genetic instability" renders the infected cell susceptible to move, along a number of stages, towards full malignancy. Little is known about these events and their causes; we present some theoretical possibilities. Bovine leukaemia virus infection has a worldwide distribution. In temperate climates, the virus spreads mostly via iatrogenic transfer of infected lymphocytes. In warm climates and in areas heavily populated by haematophagous insects, there are indications of insect-borne propagation of the virus.

The diagnosis of enzootic bovine leukosis.

This paper reviews the clinical and virological diagnostic procedures for enzootic bovine leukosis (EBL). The clinical diagnosis must be always confirmed by a specific laboratory test for Bovine Leukaemia Virus (BLV). Many virological tests were proposed. The sensitivity of all the diagnostic methods is sufficient to do an early detection of a BLV infection on an individual base. Advantages of the highly sensitive methods like RIA and ELISA appear when the samples to be tested have naturally very low antibody titers (individual milk, bulk milk, pooled sera).

Detection of B and T cells, with lectins or antibodies, in healthy and bovine leukemia virus-infected cattle.

Lectins, polyclonal antibodies and monoclonal antibodies (MAbs) were evaluated as markers for bovine lymphocytes obtained from healthy animals and from cattle infected with bovine leukemia virus (BLV). In the blood from healthy cattle the proportion of cells identified as T lymphocytes with the lectin Helix pomatia (HP) (67.8 +/- 6.2%) using the indirect immunofluorescence technique was similar to the proportion of cells identified by the MAbs P5 (66.1 +/- 3.8%) and BLT-1 (59.8 +/- 7.1%). The proportion of B cells in blood from healthy animals identified with a polyclonal antibody to bovine IgM (18.0%) was similar to that identified with a MAb to bovine IgM (16.2%). However, greater variation between individual values was detected with the MAb (SD = 8.2) than with the polyclonal antibody (SD = 4.0). In the blood from BLV-infected cattle with persistent lymphocytosis, both the polyclonal and the MAb revealed a threefold increase of B cells. A proportion of the B cells had an increased amount of immunoglobulin molecules in their plasma membrane as indicated by flow cytometry. The proportion of T lymphocytes, identified by the MAb P5, was reduced to one-third of that in non-infected cattle. The indirect HP labelling gave inconsistent results and seems not to detect solely T lymphocytes among blood lymphocytes from BLV-infected cattle.

FACS analysis of bovine leukemia virus (BLV)-infected cell lines with monoclonal antibodies (mAbs) to B cells and to monocytes/macrophages.

The eighteen monoclonal antibodies (mAbs) to B cells and the fourteen mAbs to accessory cells submitted to the workshop were analysed by FACS on three established, bovine leukemia virus (BLV)-infected bovine cell lines. Several mAbs of previously defined specificity were run in parallel. This analysis allowed us to gain further insight on the precise phenotype of those peculiar cells and to cluster the submitted mAbs according to their staining patterns. The BLV-infected cell lines seemed to belong to the B cell type though some of them lack detectable surface immunoglobulins. Moreover, all lines express the CD5 T cell marker and several myeloid markers.

[Ancient methods of animal disease prevention in Belgium]. / Les anciennes méthodes de prophylaxie des maladies animales en Belgique.

The author describes traditional methods of animal disease control in Belgium and the evolution of these methods up to the present time. Evidence is drawn mainly from Belgian law. The principles of hygienic prophylaxis, which have required little modification over the passage of time, were set out at the beginning of the 18th century by Lancisi and Bates, physicians to Pope Clement XI and King George I of Great Britain, respectively. These principles were immediately incorporated into Belgian law. However, it was not until the second half of the 19th century that they were applied correctly and with success.

Bovine leukaemia virus and enzootic bovine leukosis.

Infection of bovines with bovine leukaemia virus (BLV) manifests itself in either of two ways: 30-70% of carriers develop persistent lymphocytosis (PL), with the viral genome integrated at a large number of different sites in the DNA of the affected B-lymphocytes, without causing any chromosomal abnormalities. Only 0,1-10% of carriers develop lymphoid tumours, which also consist of B-lymphocytes. In contrast to PL, however, they are of mono- or oligoclonal origin in terms of the integration site, which is characteristic for each tumour. All cells contain one or more copies of the viral genome, chromosomal aberrations are common and if deletions are present they are invariably found in the 5'-half of the virus DNA sequence. In both types of affected cells transcription is repressed in vivo, but transient virus production can be induced in vitro and detected by means of syncytia induction or haemagglutination. In vivo production of virus in some unknown cell is suggested by the presence of high antibody titres in infected animals, especially against the envelope glycoprotein gp51. This can be detected by various techniques such as immunodiffusion, radioimmune assay or ELISA. Monoclonal antibodies against gp51 have revealed 8 epitopes, 3 of which are recognized by neutralizing antibodies and one by a cytolytic antibody. The BLV genome, about 9 kb in size, have been cloned, and some of the information obtained on its molecular structure and function is discussed. It codes for at least 4 non-glycosylated and 2 glycoproteins. Of special interest is the recently discovered serological relationship between some of the non-glycosylated proteins and those of the human T-cell leukaemia virus. The functional role of BLV in leukaemogenesis is largely unknown. The presence of the viral genome seems to be necessary for the maintenance of the transformed state, but not its continuous expression nor an LTR-mediated promotion of transcription of cellular genes. No oncogene is carried by the virus. Although bovine leukosis is not of major economic importance, its eradication is desirable and feasible in countries with a relatively low incidence, by means of testing and elimination. For endemic situations vaccination would be preferable, and distinct possibilities exist for the development of gp51 based vaccines.